Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Alan Menter

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Expert Opinion on Pharmacotherapy|March 23, 2018
Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areasDario Kivelevitch, Jillian Frieder, Ian Watson, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
The Evolving Landscape of Psoriasis TreatmentApril W Armstrong, Kenneth B Gordon, M Alan Menter, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Common and Not-So-Common Comorbidities of PsoriasisM Alan Menter, April W Armstrong, Kenneth B Gordon, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Practical Strategies for Optimizing Management of PsoriasisJashin J Wu, April W Armstrong, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|August 2, 2003
Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authorsM Alan Menter, Gerald C Krueger, Steven R Feldman, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.
Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous diseaseAntoinette Day, Amanda K Abramson, Mahir Patel, et al.
Plastic and Reconstructive Surgery|September 16, 2003
Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar linesJean D Carruthers, Nicolas J Lowe, M Alan Menter, et al.
Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous diseaseMary E Horner, Amanda K Abramson, Richard B Warren, et al.
Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Genodermatoses and inflammatory conditionsElizabeth G Wilder, Jillian Frieder, Suraj Sulhan, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Expert Opinion on Pharmacotherapy|March 23, 2018
Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areasDario Kivelevitch, Jillian Frieder, Ian Watson, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
The Evolving Landscape of Psoriasis TreatmentApril W Armstrong, Kenneth B Gordon, M Alan Menter, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Common and Not-So-Common Comorbidities of PsoriasisM Alan Menter, April W Armstrong, Kenneth B Gordon, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Practical Strategies for Optimizing Management of PsoriasisJashin J Wu, April W Armstrong, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|August 2, 2003
Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authorsM Alan Menter, Gerald C Krueger, Steven R Feldman, et al.
Seminars in Cutaneous Medicine and Surgery|April 4, 2018
Treating to Target-A Realistic Goal in Psoriasis?Kenneth B Gordon, April W Armstrong, M Alan Menter, et al.
Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous diseaseAntoinette Day, Amanda K Abramson, Mahir Patel, et al.
Plastic and Reconstructive Surgery|September 16, 2003
Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar linesJean D Carruthers, Nicolas J Lowe, M Alan Menter, et al.
Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous diseaseMary E Horner, Amanda K Abramson, Richard B Warren, et al.
Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Genodermatoses and inflammatory conditionsElizabeth G Wilder, Jillian Frieder, Suraj Sulhan, et al.
Pageof 4